Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22117787 | 1.00 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL22117653 | 1.00 | CRBN (1.00) | CRBNDDB1 | |
| Hydrochloric Acid SCHEMBL22117857 | 0.99 | CRBN (0.97) | CRBNDDB1 | |
| Bromide SCHEMBL22128737 | 0.99 | CRBN (0.97) | CRBNDDB1 | |
| Trifluoroacetic Acid SCHEMBL22117817 | 0.89 | CRBN (0.79) | CRBNDDB1 | |
| SCHEMBL27292751 | 0.84 | DDB1 (0.72) | CRBNDDB1 | |
| SCHEMBL24290121 | 0.84 | DDB1 (0.72) | CRBNDDB1 | |
| SCHEMBL21965746 | 0.84 | DDB1 (0.72) | CRBNDDB1 | |
| SCHEMBL21965932 | 0.84 | DDB1 (0.72) | CRBNDDB1 | |
| SCHEMBL21965375 | 0.84 | DDB1 (0.72) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615453-A4 | COMBINATION THERAPY WITH SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250382292-A1 | COMPOUNDS FOR TREATING LIGHT CHAIN AMYLOIDOSIS | PROTEGO BIOPHARMA INC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4355741-B1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4615453-A1 | COMBINATION THERAPY WITH SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615453-A1 | COMBINATION THERAPY WITH SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4171567-B1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12404241-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| CN-120152718-A | Combination therapy with substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds | 百时美施贵宝公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120152718-A | Combination therapy with substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds | 百时美施贵宝公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250188056-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| CN-113453681-A | Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same | 细胞基因公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-113453681-A | Substituted 3- ((3-aminophenyl) amino) piperidine-2, 6-dione compounds, compositions thereof, and methods of treatment using the same | 细胞基因公司 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020132016-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132016-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132014-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132014-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200199073-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2020-06-25 | — | — | US | disclosed |
| US-20200199073-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2020-06-25 | — | — | US | disclosed |
| US-20200199074-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-20200199074-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199073-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | CRBN 290/4885DDB1 1552/4885 |
| US-20200199074-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | CRBN 250/4885DDB1 1288/4885 |
| US-20250188056-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, ESRRA | CRBN 1/4885DDB1 935/4885 |
| US-20250382292-A1 | COMPOUNDS FOR TREATING LIGHT CHAIN AMYLOIDOSIS | TTR, CRYAA, BCL6 | CRBN 42/4885DDB1 1449/4885 |
| US-12404241-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | CRBN 290/4885DDB1 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.